In conclusion, the research indicates that the oral administration of LP22A3 might serve as a viable treatment approach for IBD owing to its capacity to stimulate the production of TGF‐β, enhance the presence of anti‐inflammatory CD103+DCs, and facilitate the development of Foxp3+Tregs. Here, TGFB1 is linked to irritable bowel syndrome.